Barts Health NHS Trust
London, United Kingdom
30 recruiting
Showing 1–20 of 61 trials
Recruiting
Phase 3
Low INR to Minimize Bleeding With Mechanical Valves Trial
Bleeding Post-mechanical Valve ReplacementThromboembolism Post-mechanical Valve Replacement
Population Health Research Institute2,625 enrolled35 locationsNCT03636295
Recruiting
Phase 2Phase 3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Chronic Hepatitis D
Mirum Pharmaceuticals, Inc.120 enrolled35 locationsNCT07454837
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled356 locationsNCT05633654
Recruiting
Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease
Acute Coronary SyndromeAtherosclerosisInflammation+2 more
Queen Mary University of London6,000 enrolled1 locationNCT06327984
Recruiting
New bioMarkers tO straTIfy cOlorectal caNcer Referrals
Colorectal CarcinomaColorectal AdenomaPolyp
Queen Mary University of London582 enrolled1 locationNCT07035691
Recruiting
Phase 2Phase 3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer
Hoffmann-La Roche650 enrolled109 locationsNCT07413939
Recruiting
Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.260 enrolled89 locationsNCT05968326
Recruiting
Phase 3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC530 enrolled144 locationsNCT07499232
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled270 locationsNCT06152575
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
HER2-negative Breast CancerAdvanced Breast CancerER Positive Breast Cancer+1 more
MedSIR300 enrolled99 locationsNCT06382948
Recruiting
Phase 3
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.172 enrolled48 locationsNCT07200908
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled394 locationsNCT07116967
Recruiting
OSTEOMICS: Identifying Regulators of Bone Homeostasis
Bone FractureOsteoporosisBone Diseases+2 more
Relation Therapeutics2,000 enrolled8 locationsNCT05732870
Recruiting
Not Applicable
Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple Sclerosis
Multiple Sclerosis
Queen Mary University of London1,336 enrolled1 locationNCT07111637
Recruiting
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting
The Oxford Risk Factors And Non-Invasive Imaging Study
Cardiovascular DiseasesCardiovascular Risk Factors
University of Oxford250,000 enrolled45 locationsNCT05169333
Recruiting
Phase 2
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
CellCentric Ltd.100 enrolled30 locationsNCT07096778
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerHormone Receptor-Positive Breast CarcinomaAdvanced Breast Carcinoma
MedSIR200 enrolled79 locationsNCT06486883
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Phase 2Phase 3
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Colitis Ulcerative
Bristol-Myers Squibb120 enrolled90 locationsNCT05076175